Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

Table 2 Characteristics and demographic information of eligible studies

Author	Year	Treatment	HCC stage	AFP change level (%)	No. of patients
					Study size (n = 974)	M/F (776/198)	AFP response (n = 463)
Chen et al[21]	2005	Sys/thalidomide	I-III	50	42	33/9	10 (23.8%)
Chan et al[20]	2009	Sys/doxorubicin or PIAF	I-III	20	117	104/13	47 (40.2%)
Riaz et al[27]	2009	Loc/chemoembolization or radioembolization	I-IV	50	125	91/34	81 (64.8%)
Vora et al[29]	2009	Sys/five systemic regimens	I-III	50	107	78/29	18 (16.8%)
Shao et al[28]	2010	Sys/Antiantiogenic agents	I-II	20	72	65/7	12 (16.7%)
Kim et al[23]	2011	Loc/chemoradiotherapy	III-IV	50	149	127/22	101 (67.8%)
Yau et al[30]	2011	Sys/sorafenib	II-IV	20	41	36/5	9 (21.9%)
Kao et al[22]	2012	Loc/radiofrequency ablation	I-III	20	58	34/24	46 (79.3%)
Lee et al[24]	2012/H	Loc/HAIC	III-IV	20	60	49/11	25 (41.7%)
Lee et al[24]	2012/C	Loc/CCRT	III-IV	20	67	55/12	52 (77.6%)
Memon et al[25]	2012	Loc/transarterialtherapy	I-III	50	51	30/21	30 (58.8%)
Personeni et al[26]	2012	Sys/sorafenib	I-III	20	85	74/11	32 (37.6%)

Sys: System treatment; Loc: Locoregional therapy; HAIC: Hepatic artery infusion chemotherapy; CCRT: Concurrent chemoradiation therapy. 2012/H: HAIC study of Lee et al; 2012/C: CCRT study of Lee et al; M/F: Male/female. HCC: Hepatocellular carcinoma; AFP: α-fetoprotein.